PDGFRA and neoplasm: Consequently, we detected PDGFRA gain in 11 tumor samples (10.3%) and PDGFRA amplification in 20 tumor samples (18.7%); the remaining 76 samples (71.0%) harbored no PDGFRA gain/amplification.